Delivery Order SPE2DB22D1103-SPE2DB24FTFY5
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic (semaglutide) 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has a ceiling value of $7,828.02 and a period of performance ending on July 10, 2025. This is a firm-fixed-price contract, and there is no set-aside designation, indicating open...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has a ceiling value of $13,019.81 and a period of performance that runs through July 2, 2025. It is a firm-fixed-price contract, with no set-aside designation, indicating...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has a ceiling value of $21,266.51 and a period of performance through August 14, 2024. It is a firm-fixed price contract, and there is no set-aside designation. AmerisourceBergen holds a large Indefinite...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has a firm fixed-price of $10,653.96 and a performance period through March 31, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL, a medication used to treat type 2 diabetes. The contract has a ceiling value of $4,713.24 and is a firm fixed-price delivery order with a completion date of May 6, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic (semaglutide) 0.25-0.5 mg/dose pen 3 mL, a medication used to treat type 2 diabetes. The contract has a ceiling value of $47,005.89 and a period of performance through June 6, 2025. It is a firm fixed-price contract, and there is no set-aside designation, indicating...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a ceiling value of $57,900.75 and a period of performance through April 30, 2025. It is a firm-fixed-price contract, without any set-aside designation, indicating open competition....
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract has a ceiling value of $12,582.29 and a performance period through April 2025. It is a firm-fixed-price contract, without any set-aside designation, indicating open competition. AmerisourceBergen Drug...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens. The contract has a ceiling value of $68,725.27 and a period of performance through July 9, 2025. It is a firm-fixed price contract with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,989.58 firm fixed-price contract is for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of March 5, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB24FTFY5Delivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic (Semaglutide) 0.25-0.5 mg/dose pens, a medication used to treat type 2 diabetes. The contract has a ceiling value of $4,930.65 and a period of performance through March 4, 2024. It is a firm-fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 3/1/24 |